- Show all
- Alicaforsen - review papers
- Alicaforsen - treatment case series papers
- Alicaforsen - Phase 2 Data
- Antisense
- Inflammatory Bowel Disease
- ICAM-1
- Renzapride - Irritable Bowel Syndrome Phase 2 Data
- Renzapride - Irritable Bowel Syndrome Phase 3 Data
- Renzapride in Systemic Scleroderma - Overall Disease Pathology
- Renzapride in Systemic Scleroderma - Gastrointestinal Involvement
- Renzapride in Cystic Fibrosis - Gastrointestinal Involvement
- Renzapride in Cystic Fibrosis - Therapeutic Effect of "Prides"
- Renzapride in Gastroparesis Phase 2 Data
Renzapride in IBS: is efficacy in the eye of the beholder?
Renzapride - Irritable Bowel Syndrome Phase 3 Data
Ford AC (2010)
Alimentary Pharmacology and Therapeutics, 113
Clinical trial: Renzapride treatment of women with irritable bowel syndrome and constipation – A double-blind, randomized, placebo-controlled, study
Renzapride - Irritable Bowel Syndrome Phase 3 Data
Lembo, A. J., Cremonini, F., Meyers, N., & Hickling, R. (2010)
Alimentary Pharmacology and Therapeutics, 31(9), 979–90
Disclaimer
The information in “published papers” is provided by Atlantic Healthcare plc, and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.